Navigation Links
Novel cancer vaccine holds promise against ovarian cancer, mesothelioma
Date:3/5/2014

A novel approach to cancer immunotherapy strategies designed to induce the immune system to attack cancer cells may provide a new and cost-effective weapon against some of the most deadly tumors, including ovarian cancer and mesothelioma. Investigators from the Massachusetts General Hospital (MGH) Vaccine and Immunotherapy Center report in the Journal of Hematology & Oncology that a protein engineered to combine a molecule targeting a tumor-cell-surface antigen with another protein that stimulates several immune functions prolonged survival in animal models of both tumors.

"Some approaches to creating cancer vaccines begin by extracting a patient's own immune cells, priming them with tumor antigens and returning them to the patient, a process that is complex and expensive," says Mark Poznansky, MD, PhD, director of the MGH Vaccine and Immunotherapy Center and senior author of the report. "Our study describes a very practical, potentially broadly applicable and low-cost approach that could be used by oncologists everywhere, not just in facilities able to harvest and handle patient's cells."

The MGH team's vaccine stimulates the patient's own dendritic cells, a type of immune cell that monitors an organism's internal environment for the presence of viruses or bacteria, ingests and digests pathogens encountered, and displays antigens from those pathogens on their surface to direct the activity of other immune cells. As noted above, existing cancer vaccines that use dendritic cells require extracting cells from a patient's blood, treating them with an engineered protein or nucleic acid that combines tumor antigens with immune-stimulating molecules, and returning the activated dendritic cells to the patient.

The approach developed by the MGH team starts with the engineered protein, which in this case fuses an antibody fragment targeting a protein called mesothelin expressed on the surface of such tumors as mesothelioma, ovarian cancer and pancreatic cancer to a protein from the tuberculosis bacteria that stimulates the activity of dendritic and other immune cells. In this system, the dendritic cells are activated and targeted against tumor cells while remaining inside the patient's body.

In the experiments described in the paper, the MGH team confirmed that their mesothelin-targeting fusion protein binds to mesothelin on either ovarian cancer or mesothelioma cells, activates dendritic cells, and enhances the cells' processing and presentation of several different tumor antigens, inducing a number of T-cell-based immune responses. In mouse models of both tumors, treatment with the fusion protein significantly slowed tumor growth and extended survival, probably through the activity of cytotoxic CD8 T cells.

"Many patients with advanced cancers don't have enough functioning immune cells to be harvested to make a vaccine, but our protein can be made in unlimited amounts to work with the immune cells patients have remaining," explains study co-author Jeffrey Gelfand, MD, senior scientist at the Vaccine and Immunotherapy Center. "We have created a potentially much less expensive approach to making a therapeutic cancer vaccine that, while targeting a single tumor antigen, generates an immune response against multiple antigens. Now if we can combine this with newly-described ways to remove the immune system's "brakes" regulatory functions that normally suppress persistent T-cell activity the combination could dramatically enhance cancer immunotherapy."

Poznansky adds that the tumors that might be treated with the mesothelin-targeting vaccine ovarian cancer, pancreatic cancer and mesothelioma all have poor survival rates. "Immunotherapy is generally nontoxic, so this vaccine has the potential of safely extending survival and reducing the effects of these tumors, possibly even cutting the risk of recurrence. We believe that this approach could ultimately be used to target any type of cancer and are currently investigating an improved targeting approach using personalized antigens." The MGH team just received a two-year grant from the Department of Defense Congressionally Directed Medical Research Program to continue their research.


'/>"/>
Contact: Katie Marquedant
kmarquedant@partners.org
617-726-0337
Massachusetts General Hospital
Source:Eurekalert  

Related medicine news :

1. A novel treatment may reduce myocardial infarction size
2. A new target for cancer and diabetes: A novel role for the adaptor protein p66shc in regulating glucose metabolism
3. Novel compound keeps Parkinsons symptoms at bay in mice
4. New company to develop novel gene therapies
5. Novel technique increases detection rate in screening mammography
6. Researchers find novel approach for controlling deadly C. difficile infections
7. Novel genes determine division of labor in insect societies
8. Novel biomarker approach suggests new avenues to improve schizophrenia disease management
9. Development of a novel dual JAK/Src kinase inhibitor
10. Jesus Was Not Born On December 25th - Controversial New Novel Tells Compelling Story About His Birth, Life and Death
11. Fatigue, a common side effect of breast cancer treatment, evaluated in novel patient study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Novel cancer vaccine holds promise against ovarian cancer, mesothelioma
(Date:1/23/2017)... ... ... Valentine’s Day is a time when many people celebrate romance and love by giving cards, ... for the ideal present, Atlanta-based Perimeter Plastic Surgery is offering a Valentine’s Day ... $200 and get $50 free. , “A lot of people just buy the more ...
(Date:1/22/2017)... Aliso Viejo, California (PRWEB) , ... January 22, 2017 , ... ... in Photo Cloud to create a beautiful 3D slideshow with complete ease," said Christina ... from the Generators browser to place in the FCPX timeline. Presets include ...
(Date:1/21/2017)... ... January 21, 2017 , ... Salveo for life, a company that distributes ... to the United States as part of its presence to expand its market reach. ... to reduce the productions of nasty toxins as a result of drinking alcohol, eliminating ...
(Date:1/21/2017)... ... 2017 , ... Phytocéane invites you to take an exotic journey ... world with ZANZIBAR SHOWER GEL. Inspired by the beauty of Zanzibar, a Tanzanian archipelago ... moisturizing vegetal coral to create this gentle, crystal-clear shower gel to cleanse the body ...
(Date:1/21/2017)... CA (PRWEB) , ... January 21, 2017 , ... ... opening of its new medical office in Petaluma, located at 167 Lynch Creek ... room, access to SRO sports medicine and rehabilitation services and on-site ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... , Jan. 20, 2017 ARMO BioSciences, ... clinical data on the Company,s lead investigational immuno-oncology drug ... co-sponsored by the American Society of Clinical Oncology (ASCO), ... Francisco, CA. "AM0010 induces ... CD8 + T cells in the blood and ...
(Date:1/20/2017)... DUBLIN , Jan 20, 2017 ... Laboratory Testing Market By Type ([CBC, HGB/HCT, BMP, BUN Creatinine, Electrolyte ... Panel), By End-use, And Segment Forecasts, 2013 - 2024" report ... ... USD 198.5 billion by 2024 Introduction of innovative solutions ...
(Date:1/20/2017)... Research and Markets has announced the addition of ... report to their offering. ... This research service on the global pharmaceutical stability ... a snapshot of the key participants in the market. ... 2016 to 2020. The market is expected to grow at a ...
Breaking Medicine Technology: